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Abstract - Given the current situation of the third and the 
worst outbreak of Ebola Virus disease in Africa and of course in 
the world, there have been rising concerns on the evolution of 
different strains of Ebola virus that have been discovered and 
isolated during these outbreaks. This enough is a compelling 
warning of impending more virulent strains future outbreaks 
with devastating consequences. In events that culminate in the 
loss of vascular integrity, release of cyclooxygenase II (COX II) 
which results in pain, diarrhea and even shock, Ebola virus 
‘engineers’ the host cells to synthesize the virus’ proteins into 
the body instead of the normal host proteins. Ebola virus 
attaches itself to the cell membrane and the viral RNA is 
released into the cytoplasm where it directs the synthesis of 
new viral proteins and genetic material. New viral genomes are 
rapidly coated in protein to create cores. Ebola virus RNA 
polymerase binds to a single promoter located at the 3' end of 
the genome. Genes close to the 3' end of the genome are 
transcribed in greatest abundance, whereas those toward the 
5' end are least likely to be transcribed. The gene order is, 
therefore, a simple but effective form of transcriptional 
regulation. 
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Introduction 
 
A wise saying I once heard from Chief AfeBabalola (SAN) 
says “if you want to keep anything from a black man you 
just hide it in a book.” Why? It is because we do not have 
a good disposition towards empirical application of 
theoretical principles in solving societal maladies and 
challenges. In the light of recent events surrounding the 
bioterrorism facing several West African countries 
including Sierra Leone, Guinea, Liberia and now 
spreading to Nigeria my country, I have developed a 
suggestive and an insightful quest into answering the 
insuperable challenge posed to us by the ravaging Ebola 
hemorrhagic viral disease. 
 
I got livid by the way Africans seem helpless and are now 
turning to entreat the United States to salvage the 
situation which started in December 2013 in Guinea and 
has continued to spread for several months in which 
thousands have been infected and hundreds have died.  
I hereby write to give my own little contribution on the 
possible way out of our current predicament. 
Nevertheless, the role of developed countries in 
salvaging the situation cannot be overemphasized in 
putting an end to this seemingly threat to humanity. 
Collective efforts are needed in providing funds to the 
affected countries in order to put stringent measures in 
place in curbing the spread.  
 
In order to make this research work self-sufficient on the 
subject of matter, certain information have been extracted 
from reliable sources with necessary references given in 
the bibliography section provided at the end to credit 
others’ work and contribution in order to avoid 
plagiarism. 
 
Overview Of Ebola Hemorrhagic Viral Disease 
 
Ebola virus disease (EVD) is a severe viral disease 
(which is often fatal) that affects mammals, including 
humans. According to Baltimore classification system of 
viruses which is based on the mode of replication and 
genome type, Ebola virus can be placed in group 5 
together with the negative-sense single-stranded RNA 
viruses.  
 
 GENOME: Single stranded negative sense RNA 
 Order: Mononegavirales 
 Family: Filoviridae 
 Genus: Ebola like viruses 
 Species: Ebola 
 
Genus Ebolavirus is 1 of 3 members of 
the Filoviridae family (filovirus), along with genus 
Marburgvirus and genus Cytomegalovirus.  
 
Genus Ebolavirus comprises 5 distinct species: 
 
1. Bundibugyoebolavirus (BDBV) 
2. Zaire ebolavirus (EBOV) 
3. Reston ebolavirus (RESTV) 
4. Sudan ebolavirus (SUDV) 
5. Taï Forest ebolavirus (TAFV).
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Ebola Virus As Seen Under the Microscope 
 
BundibugyoEbola virus, Zaire Ebola virus, and Sudan 
Ebola virus have been associated with large Ebola virus 
disease outbreaks in Africa, whereas Reston Ebola virus 
and Taï Forest Ebola virus have not. The Reston Ebola 
virus species, found in Philippines and the People’s 
Republic of China, can infect humans, but no illness or 
death in humans from this species has been reported to 
date.   
Epidemiology 
 
The first documented case of Ebola virus was in 1976 in 
two simultaneous outbreaks at Nzara, and also at 
Yambuku in Sudan and the Democratic Republic of Congo 
respectively. The latter was in a village situated near the 
Ebola River, from which the disease takes its name.
Year Country Ebolavirus species Cases Deaths Case Fatality 
2012 Democratic Republic of Congo Bundibugyo 57 29 51% 
2012 Uganda Sudan 7 4 57% 
2012 Uganda Sudan 24 17 71% 
2011 Uganda Sudan 1 1 100% 
2008 Democratic Republic of Congo Zaire 32 14 44% 
2007 Uganda Bundibugyo 149 37 25% 
2007 Democratic Republic of Congo Zaire 264 187 71% 
2005 Congo Zaire 12 10 83% 
2004 Sudan Sudan 17 7 41% 
2003 (Nov-Dec) Congo Zaire 35 29 83% 
2003 (Jan-Apr) Congo Zaire 143 128 90% 
2001-2002 Congo Zaire 59 44 75% 
2001-2002 Gabon Zaire 65 53 82% 
2000 Uganda Sudan 425 224 53% 
1996 South Africa (ex-Gabon) Zaire 1 1 100% 
1996 (Jul-Dec) Gabon Zaire 60 45 75% 
1996 (Jan-Apr) Gabon Zaire 31 21 68% 
1995 Democratic Republic of Congo Zaire 315 254 81% 
1994 Cote d'Ivoire Taï Forest 1 0 0% 
1994 Gabon Zaire 52 31 60% 
1979 Sudan Sudan 34 22 65% 
1977 Democratic Republic of Congo Zaire 1 1 100% 
1976 Sudan Sudan 284 151 53% 
1976 Democratic Republic of Congo Zaire 318 280 88% 
Extracted from: http://www.who.int/mediacentre/factsheets/fs103/en/ 
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The first known case, a 44-year old male instructor at the 
Yambuku Mission School, came to the Mission hospital on 
26 August 1976 with a febrile illness felt due to malaria. 
He was given an injection of chloroquine at the dispensary. 
The fever dropped and remained normal over the next 
four days but rose to 39.2º on 1 September. The typical 
syndrome evolved from that day and he died on 8 
September with severe haemorrhage. From the 1st of 
September to 24th of October, there were 318 cases 
resulting in 280 deaths, the epidemic peaked during the 
fourth week and then receded somewhat more gradually 
over the next 5 weeks. Date of symptom onset was not 
available for about 10% of cases. 
 
Fifty-five villages of less than 5,000 persons had cases. All 
infected villages in the epidemic area were within 60 km 
of Yambuku. This area includes about 100 villages. The 
larger towns of Abumombazi and Bumba, about 100 km to 
the north and south, respectively, had imported cases, as 
did Kinshasa, 1 100 km to the south-west. The large 
majority of affected villages were along roads running east 
and west of Yambuku, along which were located more 
villages than the north-south road. About 43 of 73 villages 
in the Yandongi collectivity were affected. This collectivity 
had an attack rate of 8.0 cases per 1,000 persons. 
 
The epidemic spread was relatively slow in the epidemic 
area during the initial outbreak. Within the first two weeks 
after the onset, the epidemic cases were occurring no 
further than 30 km from Yambuku. Almost another two 
weeks passed before a sick nursing sister was evacuated 
to Kinshasa. It was over a month until cases were 
imported into Abumombazi and Bumba. The mean 
duration of active disease was 26 days per locality and 
ranged from 1 to 55 days. At the Yambuku Mission 
Hospital, where all staff members contacted patients or 
instruments used for treating patients, 13 of 17 hospital 
employees acquired the disease and 11 died. 
 
In Nigeria so far, about 21 cases have been recorded with 
8 deaths, most of whom had primary contact with Patrick 
Sawyer (the Liberian that introduced the virus to Nigeria). 
The painful death of DrAmeyoAdadevoh and others left an 
imprint on the nation, forcing her to spring up fast and rise 
to the situation.
 
 
 
 
However, the fact that the health sector in Africa generally 
is relatively poor and not yet at its best is consequent of 
the rapid spread of the disease from the origin in 
Democratic Republic of Congo to other west African 
countries without being contained till date. This has also 
led to the frequent infection of health workers owing to 
lack or inadequacy of preventive clothings. 
 
Incubation Period  
 
This is the interval between invasion of the body by an 
infecting organism and the appearance of the first sign or 
symptom it causes. Symptoms typically start two days to 
three weeks after contracting the virus, with a fever, sore 
throat, muscle pains, and headaches. Male survivors may 
still be able to transmit the disease via semen for nearly 
two months. Hence, it is possible to have been infected 
with the disease and not even know specifically during 
this period of incubation within which the virus weakens 
and even destroys the immune system.  
 
Mode of Transmission  
  
Ebola is introduced into the human population through 
close contact with the blood, secretions, organs or other 
body fluids of infected animals. In Africa, infection has 
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been documented through unprotected and indiscriminate 
handling of infected chimpanzees, gorillas, fruit bats, 
monkeys, forest antelopes and porcupines found ill or 
dead in the rainforest. 
 
Ebola then spreads in the community through human-to-
human transmission, with infection resulting from direct 
contact (through broken skin or mucous membranes) with 
the blood, sweat, semen, breast milk, salivary secretions, 
organs or other body fluids of infected people. Burial 
ceremonies in which mourners and embalmers have direct 
contact with the body of the deceased person can also play 
a crucial role in the transmission of Ebola Virus. Also, 
indirect contact with environments contaminated with 
such fluids (blood, sweat, semen, breast milk, salivary 
secretions). 
 
Health-care workers have frequently been infected while 
treating patients with suspected or confirmed Ebola Virus 
Disease (EVD). This has occurred through close contacts 
with patients when infection control precautions are not 
strictly practiced or may occur as a result of mistakes in 
the line of caring for an infected patient (one of the health 
hazards in medical practices). 
 
Among workers in contact with monkeys or pigs infected 
with Reston Ebola virus, several infections have been 
documented in people who were clinically asymptomatic. 
Thus, Reston Ebola virus appears less capable of causing 
disease in humans compared to other strains of the Ebola 
virus. [2] 
 
Airborne transmission has not been documented during 
previous EVD outbreaks. They are, however, infectious as 
breathable 0.8–1.2 micrometer laboratory generated 
droplets; because of this potential route of infection, these 
viruses have been classified as a Category A biological 
weapon (organisms that can be used purposefully 
weapons in bioterrorism or biological warfare [BW] and 
result in high mortality, cause major negative influence on 
public health, may cause public panic).  
 
Thus, I state that Ebola Virus, from this laboratory 
micropipette experiment is very likely to become airborne 
as it mutates. Also, if an Ebola positive patient sneezes 
(vigorously), those who are close to such person at that 
point should be quarantined and closely monitored. 
 
Recently the virus has been shown to travel without 
contact from pigs to non-human primates. However, it is 
not certain for how long this virus can stay outside the 
host environment and still be able to cause infection.  
 
Bats drop partially eaten fruits and pulp, then land 
mammals such as gorillas and duikers feed on these fallen 
fruits. This chain of events forms a possible indirect means 
of transmission from the natural host to animal 
populations, which has led to research towards viral 
shedding in the saliva of bats. Fruit production, animal 
behavior, and other factors vary at different times and 
places that may trigger outbreaks among animal and 
human populations.  
 
Reservoir 
 
Bats are considered the most likely natural reservoir of 
the Ebola virus (EBOV); plants, arthropods, and birds have 
also been considered. Bats were known to reside in the 
cotton factory in which the first cases for the 1976 and 
1979 outbreaks were observed, and they have also been 
implicated in Marburg virus infections in 1975 and 
1980. Of the 24 plant species and 19 vertebrate species 
experimentally inoculated with EBOV, only bats became 
infected. The absence of clinical signs in these bats is 
characteristic of a reservoir species. In a 2002–2003 
survey of 1,030 animals including 679 bats 
from Gabon and the Republic of the Congo, 13 fruit bats 
were found to contain EBOV RNA fragments. As of 2005, 
three types of fruit bats (Hypsignathus Monstrosus, 
Epomopsfranqueti, and Myonycteristorquata) have been 
identified as being in contact with EBOV. They are now 
suspected to represent the EBOV reservoir hosts.  
 
Cycle of Events Inside Human Hosts 
 
A good understanding of this is needed if a meaningful 
vaccine will be developed.  The Ebolavirus life cycle begins 
with virion attachment to specific cell-surface receptors. 
This is followed by fusion of the virion envelope with 
cellular membranes and the concomitant release of the 
virus nucleocapsid into the cytosol. The viral RNA 
polymerase, encoded by the L gene, partially uncoats the 
nucleocapsid and transcribes the genes into positive-
strand mRNAs, which are then translated into structural 
and nonstructural proteins. Ebolavirus RNA polymerase 
binds to a single promoter located at the 3' end of the 
genome. Transcription either terminates after a gene or 
continues to the next gene downstream.  
 
This means that genes close to the 3' end of the genome 
are transcribed in the greatest abundance, whereas 
those toward the 5' end are least likely to be 
transcribed. The gene order is, therefore, a simple but 
effective form of transcriptional regulation.
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Ebola virus ‘engineers’ the host cells to synthesize the virus’ 
proteins into the body instead of the normal host proteins. 
Ebola virus attaches itself to the cell membrane at middle 
left. Viral RNA (yellow) is released into the cytoplasm where 
it directs the synthesis of new viral proteins and genetic 
material. New viral genomes are rapidly coated in protein 
to create cores. These viral cores pile up in the cell and 
migrate to the cell surface. Transmembrane proteins 
(purple) are produced which are conveyed to the cell 
surface. The cores push their way through the cell 
membrane, becoming enveloped in cell membrane and 
collecting their transmembrane proteins (spikes) as they do 
so.  Courtesy Russell Kightley Media. 
 
The most abundant protein produced is the nucleoprotein, 
whose concentration in the cell determines when the 
virus’ RNA polymerase switches from gene transcription 
to genome replication. Replication results into full-length, 
positive-strand antigenomes that are, in turn, transcribed 
into negative-strand virus progeny genome copy. Newly 
synthesized structural proteins and genomes self-
assemble and accumulate near the inside of the cell 
membrane. Virions bud off from the cell, gaining their 
envelopes from the cellular membrane they bud from. The 
mature progeny particles then infect other cells to repeat 
the cycle.    
  
Once infected by the virus, it becomes active inside the 
human host and the endothelial cells, 
mononuclear phagocytes, and hepatocytes are the main 
targets of infection. After infection, a secreted glycoprotein 
(sGP) known as the Ebola virus glycoprotein (EGP) is 
synthesized. The EGP forms a trimeric complex, which 
binds the virus to the endothelial cells lining the interior 
surface of blood vessels.  
The cytopathic effect, from infection in the endothelial 
cells, results in a loss of vascular integrity, hence, internal 
bleeding results, first from the tiny capillaries and then 
progresses to larger vessels which culminate in external 
bleeding. At this stage the clotting factors become affected 
due to decreased synthesis of the high molecular weight 
kinogen which initiates the intrinsic pathway in the 
coagulation cascade so blood does not clot inside (this is a 
possibility). This loss in vascular integrity continues with 
synthesis of EGP, which reduces specific integrins 
responsible for cell adhesion to the inter-cellular 
structure, and damage to the liver, which leads to 
coagulopathy.
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Ebola replication overwhelms protein synthesis in 
infected cells of host immune defenses.  The sGP forms 
a dimeric protein that interferes with the signaling 
of neutrophils (a type of the white blood cells) which 
allows the virus to evade the immune system by inhibiting 
the early stages of neutrophil activation. These white 
blood cells also serve as carriers to transport the virus 
throughout the entire body to places such as the lymph 
nodes, liver, lungs, and spleen. The presence of viral 
particles and cell damage resulting from budding causes 
the release of cytokines (to be specific, TNF-α, IL-6, IL-8, 
etc.), which are the signaling molecules for fever and 
inflammation.   
 
Clinical Manifestation 
  
Early symptoms of Ebola virus disease include sudden 
onset of fever, weakness, muscle pain, headaches and a 
sore throat. These symptoms can appear two to 21 days 
after infection. These nonspecific and atypical early 
symptoms can be mistaken for signs of diseases such as 
malaria, typhoid fever, meningitis or even the plague.  
 
The early symptoms progress to vomiting, diarrhea, 
impaired kidney and liver function and sometimes 
internal and external bleeding. Laboratory findings 
include low white blood cell and platelet counts and 
elevated liver enzymes.  
 
Protective Guidelines That Should Be Strictly 
Observed 
 
 Gowns and aprons- disposable aprons are 
recommended. Cotton gowns provide limited 
protection but are acceptable in lack of better 
ones. Gowns made of water-repellent material 
give better protection. The gown or apron should 
be left hanging in the room and changed daily or 
earlier when soiled. Although disposable aprons 
are preferable, non-disposable plastic aprons may 
be used and can be disinfected by formalin or 
alcohol due to financial and economic challenges 
in the affected countries or even burnt.  
 
 Gloves - gloves should be worn when handling 
infected materials and sites. Conventional 
disposable non-sterile plastic gloves may be 
adequate. Long sleeved disposable gloves can be 
used for protection of the arms when treating 
infected patients and when necessary (during 
sports of fluid from patients).  
 
 Masks - masks are necessary but when used they 
should be of the high efficiency filter type, which 
should provide protection for atleast 10-15 
minutes.  
 
 Hands - hand washing before and after contact 
with the patients is perhaps the most important 
measure in preventing the spread of infection. 
Either a non-medicated soap or a detergent 
antiseptic preparation should be adequate. 70% 
alcohol is more effective in removing transient as 
well as residual flora and should be used in such a 
high risk situation. 
 
 Bedpans and urinals - gloves should be worn 
when handling bedpans and urinals. The contents 
should be disposed of directly into the sluice or 
bedpan disinfector. The bedpan or urinal should 
then be heat disinfected and dried. A bedpan 
washer/disinfector and a high temperature 
washing-up machine should be available in all 
isolation units.  
 
 Wastes - all clinical wastes should be disposed 
incolour-coded bags for incineration. 
 
 Equipment - disposable or 
autoclavableequipments should be used 
whenever possible. Essential items of patient care 
such as sphygmomanometers and stethoscopes 
should be left in the room and disinfected when 
the patient is discharged or before being used on 
another patient. Hard surfaces may be disinfected 
by wiping with a phenolic or hypochlorite 
solution. Other equipment may be disinfected by 
wiping with 70% alcohol. Sphygmomanometer 
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cuffs may be disinfected by low temperature 
steam. 
 
 Needles and syringes - these should be 
disposable and placed in a hardened container 
which is sealed before disposal.  
 Linen - Vigorous bed-making should be avoided. 
Linen from infected patients should be placed in a 
colour-coded linen bag for transfer to the laundry. 
Linen which may present a hazard to the laundry 
staff and so should first be sealed in labeled bags.  
 
 Crockery and cutlery - disposable items may be 
used when a dishwasher heating the items to over 
80oC is not available. Food should be placed in 
polythene bags and discarded with other wastes 
from the isolation units.  
 
 Laboratory specimens– Containers and used 
materials should be placed in a biohazard bags.  
 
 Transporting patients - patients should be sent 
to other departments only if it is essential to do so 
even in the isolation units. The department should 
be notified in advance so that they may take 
suitable measures to prevent the spread of 
infection. This is sometimes necessary for further 
investigations in the course of treatment.  
 
Note: Under the Public Health Act 1936, the removal of 
the bodies believed to have died from highly infectious 
diseases such as Ebola Virus Disease from the hospital is 
prohibited, except for the purpose of being taken directly 
to a mortuary or being buried or cremated. Cremation is 
considered ideal for safe disposal of bodies of persons who 
have died from Ebola Virus Disease in order to minimize 
further transmission of infection. It involves the 
application of high temperature to reduce body organic 
components (cellular structures, tissues and organs) to 
basic chemical components (ashes). 
 
Developing the Vaccine 
  
There are relatively a lot of measures that can be taken 
against the Ebola virus outbreak some of which are 
mentioned in this work.  
 
 One way is to render it harmless by interrupting 
the process which culminates in the synthesis of 
Ebola virus glycoprotein (GP) that forms 
a trimeric complex (which a drug can do), which 
then binds the virus to the endothelial cells lining 
the interior surface of blood vessels causing 
hemorrhage to occur.  
 
 Interfering with the virus RNA polymerase chain 
reaction which causes the release of the 
virus nucleocapsid into the cytosol, hence 
partially uncoating the nucleocapsids 
and transcribing the genes into positive-
strand mRNAs, which are then translated into 
structural and nonstructural proteins of the virus.  
 
 Termination of its life cycle at any possible point 
including prion removal before it acquires its full 
force in combating the host (which some drugs 
can do) 
 
 Performing genome study and karyotyping to 
detect the gene responsible for rapid viral 
replication and developing a vaccine with that 
knowledge solely to trigger the antigen-antibody 
immune responses. However, going through this 
route may rather seem too ambiguous to 
comprehend and execute in certain instances.  
 
Symptomatic Treatment 
 
I am of a strong opinion that Ebola virus, looking at the 
cycle of events inside human hosts and being a viral 
disease can be best tackled with a vaccine. The 
effectiveness of a potential vaccine with the recent 
massive outbreak should be reinforced with a well 
monitored symptomatic treatment involving minimizing 
invasive procedures (due to hemorrhage and 
coagulopathy), balancing fluids and electrolytes to 
counter dehydration, monitored administration of Vitamin 
K supplements, prevention of disseminated intravascular 
coagulation (in which there is uncontrolled activation of 
clotting factors and fibrinolytic enzymes throughout small 
blood vessels; fibrin is deposited, platelets and clotting 
factors are consumed, and fibrin degradation products 
inhibit fibrin polymerization, resulting in tissue necrosis 
and bleeding), administration of pro-coagulants late in 
infection to control bleeding, maintaining 
oxygen levels, pain management, and the use of 
medications to treat bacterial or fungal secondary 
(superimposed) infections. I also will advocate a 
calculated but notwithstanding low dose of Phylloquinone 
(Vitamin K) to keep the coagulopathy and hemorrhage in 
check during the period of illness because we are dealing 
with a hemorrhagic disease. Aspirin, which acts as anti-
prostaglandin also produces anti-inflammatory effects in 
its overall anti-pyretic action (though the fact that 
Acetylsalicylic acid [Aspirin] may worsen hemorrhage 
cannot be ruled out because it works as an anti-platelet at 
low dose).Early treatment may increase the patient’s 
chance of survival; however, it is also subject to a number 
of factors such as the amount of exposure to contaminated 
body fluids, etc.  Since most patients die due to 
hypovolemic shock, it is better to control the level of body 
fluids and also give anti-shock promptly when the need 
arises at 20mils per kg in children over 30 to 60 minutes 
and constantly reviewing vital signs. 
 
However it is an increasingly interesting fact to discover 
that the reservoir and natural hosts of Ebola virus (the 
fruit bats, (Hypsignathus Monstrosus, Epomopsfranqueti, 
and Myonycteristorquata) themselves do not get infected; 
the questions thence to ask is how do these creatures 
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protect themselves? A forensic or critical (laboratory) 
analysis of their serum could help identify the specific 
antibodies that are of crucial importance to their survival. 
Also, it should be noted that since some humans have 
survived the disease upon sensitive and specific 
laboratory tests, thorough investigation to discover how 
the immune system was able to overcome will as well be 
of vital importance in overhauling the overwhelming 
outbreak.
  
 
 
 
B-lymphocyte activation by antigen binding leads to formation of antibody-secreting plasma cells and antigen-sensitive 
memory cells. 
 
Furthermore, a very interesting fact that should be looked 
into is how the fruit bats are able to survive as carriers 
and yet not dying from this deadly disease. Also, owing to 
the results of the studies done on the 1995 outbreak of 
Ebola Virus Disease in Democratic Republic of Congo 
which showed that seven out of 8 infected people survived 
after being given the blood of survivors of the disease, I 
would suggest the use the blood of long time survivors for 
the time being who would have developed antibodies that 
would combat the antigenic components in infected 
persons. However, using this therapy as well requires 
adequate screening and strict precautions in the area of 
blood donations in ensuring compatibility with cross 
matching (donor cells are mixed with recipient plasma, 
and recipient cells alsoare mixed with donor plasma; there 
should be no agglutination in both cases).  
 
NOTE: Administration of antibiotics indiscriminately 
without a convincing need should be avoided as they may 
cause more harm than good for patients infected with Ebola 
virus as they are not suffering from bacterial infection but a 
viral infection instead).  
The Potential Vaccine 
  
Since viruses cannot be grown in microbiological broths or 
on agar gels, they have to be cultured using suitable tissue 
culture techniques and cell lines such as the immortal 
HeLa cell line for isolation of viruses – obtained from 
cancer of the cervix from the late Henrietta Lacks or Vero 
cell line for the isolation of viruses – from African green 
monkey kidney. The embryo of fowls may also yield 
expected positive results but it has higher risks of being 
contaminated.  
 
The virus can be isolated or obtained and conveyed from 
the serum of infected persons or other mammals to a 
specially prepared research laboratory.  
 
Processes Involved In the Isolation of Ebola Virus 
 
 Hela cells preparation in laboratory flasks or test-
tubes. 
 
 The Hela cells are adherent cells which spread out 
across culture flasks. They are signalled to stop 
growing when adjacent cells become apposed 
together or touch each other. 
 
 When fully grown and separated into the different 
containment bottles, the cells are then infected 
with the virus in the process of inoculation.  
 
 I advocate the use of Zaire strain of Ebola virus as 
it seems to pose the most deadly threat since 
discovery in 1976 and of course in the recent 
massive outbreak across West Africa.   
 
 The set-up apparatus after inoculation is then 
incubated at 37oC   
 
 Examine the cultures for evidence of infection 
such as cytopathogenic effect (CPE), interference, 
9                                                                                                                                                            Science Journal of Medicine and Clinical Trials (ISSN: 2276-7487) 
How to Cite this Article: Emmanuel Oluwatosin Adegbite, "Therapeutic Measures against the Current Virulent Endemicity of Ebola Virus", Science 
Journal of Medicine and Clinical Trials, Volume 2014, Article ID sjmct-265, 12 Pages, 2014. doi: 10.7237/sjmct/265 
haemadsorption, and also for the presence of viral 
antigens. 
 
 Harvesting of the virus from positive cultures by 
freeze-thawing and low-speed centrifugation  
 
 The supernatant is then used as antigen (in the 
vaccine to trigger antigen-antibody immune 
responses at standardized doses coupled with 
certain adjuvants.  
 
 Virus identification by testing the antigen against 
a battery of antisera with complement fixation, 
neutralization, haemagglutination inhibition tests, 
Enzyme-linked immunosorbent assay (ELISA) and 
immunofluorescence.  
 
NOTE: In order not to alter the chemical constituents in the 
course of processing the vaccine, it will be best to first 
inactivate the virus then proceed with inoculation and the 
following steps in the bid to making the vaccine as effective 
as possible. 
 
To choose from a wide variety of methods to make this 
vaccine, I will further suggest the use of an inactivated 
vaccine and not an attenuated one. The live or attenuated 
vaccine has a higher risk of making Ebola virus turn out to 
give a more deadly and more virulent strain than the one 
we are currently contending inside (human) hosts upon 
administration of even the first shot of the vaccine. In 
respect of this factor, I will give an outline on how to go 
about inactivating the virus bearing in mind that it is easily 
killed at high temperature. The virus can be denatured or 
inactivated to weaken the replicating power of the virus. 
Its effectiveness can be confirmed at inoculation and 
weakened the more if the virus remains hyper-reactive 
following the first inactivating process. The success of 
these techniques can be detected by examination of the 
cytopathogenic effects of the attenuated virus on the 
culture cell lines. The virus can be inactivated using the 
following techniques; 
 
 
 
 
 
T-lymphocyte activation by cell surface antigen. Binding requires the presence of both foreign and normal 
histocompatibility antigens. The activating cell may be any body cell carrying an abnormal antigen or a specialized antigen 
presenting cell which has phagocytosed antigenic material. 
 
Pasteurization - Pasteurization involves increasing the 
temperature of solution to a value that will sufficiently 
denature Ebola Virus over a period of time as it does not 
matter whether the virus has an envelope or not because 
the envelope alone cannot protect the virus from such high 
temperatures. However, there are some proteins which 
have been found to act as thermal stabilizers for viruses. 
Of course, if the target protein is not heat-resistant, using 
this technique could denature that target protein as well 
as the viral impurity. Typical incubation lasts for 10 hours 
and is performed at about70°C.  The aim of this technique 
is to minimize number of times the virus will replicate 
when introduced into the human body.  
 
Ultraviolet (UV) Radiation - UV rays can damage the 
DNA of living organisms by creating nucleic acid dimers. 
However, the damages are usually not important due to 
low penetration of UVs through living tissues. UV rays can 
be used, however, to inactivate Ebola virus since the virus 
particles are small and the UV rays can reach the genetic 
material, inducing the dimerization of nucleic acids. Once 
the DNA dimerized, the virus particles cannot replicate 
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their genetic material which prevent them from spreading. 
Also, UV light in combination with riboflavin has been 
shown to be effective in reducing pathogens in blood 
transfusion products. Riboflavin and UV light damages the 
nucleic acids in viruses, bacteria, parasites, and donor 
white blood cells rendering them unable to replicate and 
cause disease. I suppose interference with ultraviolet rays 
is actually of high importance to salvage any future 
occurrence of the vaccine forming cancerous and adherent 
cells in humans following immunization (because of the 
risk in the use of the immortal Hela cells earlier 
mentioned).  
 
The use of Formalin may also yield expected positive 
results in the inactivation of Ebola virus. 
 
The effectiveness of these techniques can be evaluated by 
culture with embryonated eggs in that the more powerful 
its replicating power is in the embryo the less powerful it 
will replicate inside human hosts so enough to overwhelm 
the immune system but will be active enough to sensitize 
the immune system to produce antibodies against the 
virus at first shot. This can be reinforced with subsequent 
shots. Embryonated eggs brought in on a daily basis from 
biosecureflocks are best to be used for Ebola virus. A seed 
ampoule is used to inoculate the chick eggs during the 
inoculation phase. This is followed by a mandatory three-
day incubation period during which the virus grows to 
ensure that sufficient quantities can support further 
manufacturing. After three days, all of the eggs are candled 
to make sure there are no cracks or contamination; the 
eggs are then chilled to 2oC to 8oC to constrict vessels and 
make harvesting easier. The allantoic fluid is then 
harvested.  
 
Hence, the virus particles are destroyed and cannot 
replicate, but the virus capsid proteins are intact enough to 
be recognized by the immune system to evoke a response.  
 
Types of Specimens 
 
Specimens that may be tested for the presence of viral 
agents in infected persons are the following: 
 
Autopsy or Biopsy Specimens 
Autopsy specimens for Ebola virus isolation should be 
collected within 24 hours after death. Samples (1.0-2.5 cm 
Tubes of tissue) from sites of pathology are collected using 
separate, sterile instruments and separate sterile 
containers for each specimen to avoid cross 
contamination. Tissues are transported to the laboratory 
on wet ice or cold pack. If they cannot be tested within 48 
hours they should be frozen. 
 
Blood Specimens 
 
Although blood is not the optimal specimen for isolation of 
most viruses, it may be used for the recovery of some of 
the vector-borne viruses such as Enteroviruses, and 
Cytomegalovirus (CMV) and possibly Ebola virus as there is 
no scientific proof of non-transmittance through air. 
Specimens for Ebola virus isolation should be collected as 
soon as a viral etiology is suspected, otherwise early 
neutralizing antibody may prevent recovery of the virus 
from the blood in some cases. Either serum or leukocyte 
preparations may be used for viral isolation. For isolation 
of the virus from leukocytes, 8 ml of blood is collected into 
a tube containing an anticoagulant. Although heparin is 
often used, it is reported to inactivate herpes simplex 
virus, and therefore EDTA bottle may be preferable as an 
anticoagulant. For isolation of Ebola virus from the serum 
or blood clot, 8 ml of blood is collected aseptically without 
an anticoagulant. Blood specimens should be transported 
to the laboratory on wet ice or a cold pack, but not frozen. 
 
Others include;  
 
 Cerebrospinal Fluids (CSF) 
 Cervical Specimens 
 Rectal Swabs 
 Saliva 
 Semen Specimens 
 Stool and Urine Specimens 
 
NOTE: If a medium specifically formulated for collection of 
viral specimens is not available, a sterile, well-buffered 
bacteriological broth, such as tryptose phosphate broth, 
may be used. If no other media is available, sterile water 
may be used; however, viral recovery will be enhanced by 
the use of a protein containing media. Cotton-or Dacron-
tipped swabs are preferred for collection of specimens; 
prolonged contact with calcium alginate swabs has been 
reported to inactivate herpes simplex virus. 
 
The medium used for collection and holding of swab 
specimens should contain protein to stabilize the more 
labile viruses, and the use of media containing charcoal 
should be avoided as this may reduce viral recovery 
rates. 
 
The next sequence of events in making this vaccine 
effective and to help trigger a more vigorous immune 
response against the deadly virus will be the addition of 
excipients (pharmacologically inert substances used to 
bind contents of drugs) and necessary adjuvants (agents 
added to drugs to enhance their medical effectiveness) to 
the vaccine for an excellent result to be obtained even with 
storage of this vaccine. 
 
Aluminium Hydroxide Hydrated Gels – to promote an 
earlier, more potent and more persistent immune 
response to the active antigenic‘ingredients’ or the virus 
itself(less than 2 milligrams of the salts, and less than a 
milligram of actual aluminium). Although vaccination does 
result in a temporary increase in the amount of aluminium 
in the body of infants, this is not a lasting effect, since the 
body gets rid of most of the aluminium in just a few days. 
 Two studies from 2002 and 2011 compared the impact of 
aluminium from diet and vaccines in infants. Both of these 
found that the total amount of aluminium absorbed from 
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both sources is significantly less than the recommended 
safe maximum amount. The 2011 study concluded that 
'the benefits of using vaccines containing aluminium 
adjuvant outweigh any theoretical concerns'.  
 
Neomycin – antibiotics used to prevent growth of bacteria 
during production and storage of vaccine. However this is 
to be used only in trace amount. Antibiotics which have 
been associated with allergic reactions (such as 
penicillins, cephalosporins and sulphonamides) are not 
used in vaccines.  
 
Human Serum Albumin- as a stabilizing agent (NOT 
MORE THAN 0.3mg/dose)  
 
Preservatives can also be used to prevent the serious 
adverse effects associated with infections or 
contamination of the vaccine especially upon storage. A 
good example in trace amount is formaldehyde or 
phenoxyethanol. 
 
At the end of further laboratory studies in the employment 
and application of this research work, I suggest that three 
doses of the vaccine should be given over a calculated 
period of time to provide primary and secondary 
immunity, allowing the body to produce antibodies and 
also for the risk of not loading the system with the virus 
from the first two doses and later reinforced with the 
extant dose to provide the maximally possible immunity. 
The first shot should be strong enough to sensitize the 
memory B cells to store the information and prepare the 
body in case of subsequent attacks. I aim to couple this 
vaccine or reinforce the effectiveness the vaccine with 
immune markers like interferon alpha-n3 or Interferon 
alpha-2b proteins (which have been seen to be effective 
against viruses) so as to make it effective in people with 
weakened immunity such as people with Cancer or AIDS 
and even Diabetes.Interferons are proteins produced by 
virus-infected cells and they have the ability to prevent 
viral replication in other cells. According to Dereck 
Gatherer, a bioinformatics at Lancaster University in the 
United Kingdom, who studies viral genetics and evolution, 
immune markers such as CD4 and CD8 T lymphocytes 
which are crucial to the function of the immune system 
depleted in persons with Ebola virus, our bet in the 
development of this vaccine will be to reinforce such 
markers and possibly couple them in very minute amount 
to the vaccine to help the immune system regulate itself.
 
 
 
 
Plasma antibody levels following first and second exposures to a given antigen. 
 
Another marker to be coupled to the vaccine to maximize 
the fight against the deadly Ebola virus is a ‘gene called 
human leukocyte antigen-B which makes a protein that is 
important to the immune system. A 2007 study found that 
people with certain versions of this gene, called B*07 and 
B*14 are more likely to survive Ebola.’ 
 
In the final analysis, some people may be resistant to 
Ebola infection entirely, if they have a mutation in the gene 
called NPC1. Studies show that, when researchers take 
cells from people with NPC1 mutation and try to infect 
them with Ebola virus in a laboratory plate, these cells are 
resistant to the virus.  Hence isolation of this marker and 
adding it in a slightly significant amount can as well aid in 
overhauling the deadly disease and restoring life to our 
society. 
 
I also want to use this medium to enjoin scientists all over 
the world, most especially Africa scientists (Pharmacists 
and other researchers) who seem not to be doing enough 
for the whole world to see even in previous outbreaks to 
join in this quest of finding a lasting solution to the 
perilous viral diseases affecting mankind, animals, and 
plants. This is much more needed at this time of 
endemicity of Ebola Virus Disease because of the impact it 
has conferred on economy of the nations, discrimination of 
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affected persons, and the fear of eating bush meats by 
Africans who are used to hunting them for food; shaking of 
hands, the loss of loved-ones to the dreaded virus 
(emotionally, psychologically, and of course physically) 
and most importantly the fear of saving people dying of 
other ailments not related to Ebola across the regions 
affected. Though, several medications such as ZMAPP (by 
the MAP Pharmaceuticals), the GSK EBOV (by 
GlaxoSmithKline Pharmaceuticals) vaccines among others 
have been undergoing clinical trials in different phases. I 
am of a daunting opinion that the strain of Ebola virus we 
are dealing with currently in the outbreak in West Africa is 
likely to be different in some forms in its DNA structure 
compared with that of 1976 owing to the fact that this is 
seeming to be more virulent, leading to more deaths as it 
has been termed the worst outbreak of Ebola in history. 
Thus, we must all be at our bests in order to salvage any 
dreadful future re-occurrence as we are still battling with 
the third and worst Ebola outbreak in history.   
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